Restoring Life’s Potential

by enabling the nervous system to repair itself

Recent Press Releases

View All

NervGen Pharma to Participate in the H.C. Wainwright “HCW@Home” Series and the 2026 Bloom Burton & Co. Healthcare Investor Conference

April 13, 2026

NervGen announced that Adam Rogers, MD, President and Chief Executive Officer of NervGen, and other members of the Company’s executive leadership team, are scheduled to participate in the H.C. Wainwright “HCW@Home” series and the 2026 Bloom Burton & Co. Healthcare Investor Conference.  

Read More ›

NervGen Pharma Announces Successful End-of-Phase 2 Meeting and FDA Alignment on RESTORE, a Phase 3 Registrational Study of NVG-291 for Chronic Tetraplegia

April 07, 2026

NervGen announced the completion of a successful End-of-Phase 2 meeting with the U.S. Food and Drug Administration and alignment on RESTORE, the Company’s Phase 3 registrational study designed to evaluate NVG-291 for the treatment of chronic tetraplegia.   

READ MORE ›

NervGen Pharma Reports Full Year 2025 Financial Results and Provides Business Updates

March 31, 2026

NervGen reported its full year 2025 financial results and provided business updates. 

Read More ›

Phase 1b/2a CONNECT SCI Study for 
Individuals with Spinal Cord Injury

VIEW INFORMATION

For information regarding recruitment, the call center phone number is +1 (855) 559-6902. 

View NervGen’s Origin Story Video

VIEW VIDEO

Stay Connected

Subscribe to our mailing list to stay up to date